EirGenix Capacity Update May 2024: Large Molecule Development
Source: EirGenix Inc.
EirGenix is Taiwan's largest CDMO for mammalian and microbial-derived, clinical, and commercial manufacturing of biologics (mAbs, bi-specifics, ADC, recombinant vaccines, and pDNA). We are inspected and approved by the USFDA, Japan’s PMDA, Australia’s TGA, and the EU’s EMA. EirGenix has immediate capacity availability up to 12 x 2,000 L SUBs for mammalian cells and up to 150 L scale for microbial. The microbial capacity will increase to 350L and 1,000L by 2025.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.
Subscribe to Outsourced Pharma
X
Subscribe to Outsourced Pharma
EirGenix Inc.
This website uses cookies to ensure you get the best experience on our website. Learn more